X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs NOVARTIS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA NOVARTIS GLENMARK PHARMA/
NOVARTIS
 
P/E (TTM) x 24.5 321.8 7.6% View Chart
P/BV x 3.8 35.7 10.7% View Chart
Dividend Yield % 0.3 1.3 24.6%  

Financials

 GLENMARK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
NOVARTIS
Mar-18
GLENMARK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs993758 131.0%   
Low Rs729579 126.0%   
Sales per share (Unadj.) Rs325.5228.4 142.5%  
Earnings per share (Unadj.) Rs39.331.7 123.8%  
Cash flow per share (Unadj.) Rs48.732.8 148.5%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.5 15.5%  
Book value per share (Unadj.) Rs159.2297.1 53.6%  
Shares outstanding (eoy) m282.1724.69 1,142.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.9 90.4%   
Avg P/E ratio x21.921.1 104.0%  
P/CF ratio (eoy) x17.720.4 86.7%  
Price / Book Value ratio x5.42.2 240.4%  
Dividend payout %5.131.5 16.2%   
Avg Mkt Cap Rs m242,99116,505 1,472.2%   
No. of employees `00013.00.7 1,941.2%   
Total wages/salary Rs m16,4081,445 1,135.3%   
Avg. sales/employee Rs Th7,083.98,441.3 83.9%   
Avg. wages/employee Rs Th1,265.42,163.6 58.5%   
Avg. net profit/employee Rs Th855.11,173.1 72.9%   
INCOME DATA
Net Sales Rs m91,8575,639 1,629.0%  
Other income Rs m3741,718 21.7%   
Total revenues Rs m92,2307,357 1,253.6%   
Gross profit Rs m20,367-63 -32,587.3%  
Depreciation Rs m2,64425 10,449.4%   
Interest Rs m2,37355 4,291.5%   
Profit before tax Rs m15,7241,575 998.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827792 483.4%   
Profit after tax Rs m11,088784 1,414.9%  
Gross profit margin %22.2-1.1 -2,000.4%  
Effective tax rate %24.350.3 48.4%   
Net profit margin %12.113.9 86.9%  
BALANCE SHEET DATA
Current assets Rs m68,7469,522 722.0%   
Current liabilities Rs m27,0273,296 820.0%   
Net working cap to sales %45.4110.4 41.1%  
Current ratio x2.52.9 88.1%  
Inventory Days Days8537 232.2%  
Debtors Days Days9628 336.1%  
Net fixed assets Rs m24,13246 52,461.9%   
Share capital Rs m282123 228.7%   
"Free" reserves Rs m44,6437,213 618.9%   
Net worth Rs m44,9257,336 612.4%   
Long term debt Rs m45,3630-   
Total assets Rs m117,63911,105 1,059.3%  
Interest coverage x7.629.5 25.9%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.80.5 153.8%   
Return on assets %11.47.6 151.5%  
Return on equity %24.710.7 231.1%  
Return on capital %19.122.2 86.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15261 92,659.4%   
Fx outflow Rs m8,0843,630 222.7%   
Net fx Rs m48,068-3,570 -1,346.6%   
CASH FLOW
From Operations Rs m6,5741,610 408.4%  
From Investments Rs m-7,124687 -1,036.9%  
From Financial Activity Rs m5,432-2,677 -202.9%  
Net Cashflow Rs m1,992-380 -524.9%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 2.0 345.0%  
FIIs % 34.4 1.6 2,150.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   56,727 41,647 136.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS